Corrigendum to "Anticoagulant activity of oral rivaroxaban in healthy dogs" [Vet. J. 223 (2017) 5-11]

Affiliations

¹ Department of Clinical Sciences, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada. Electronic address: berenice.conversy@umontreal.ca.
² Department of Clinical Sciences, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada.
³ Department of Pathology and Microbiology, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada.
⁴ Department of Veterinary Biomedicine, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada.

Published Erratum

Bérénice Conversy et al. Vet J. 2020 Sep.

. 2020 Sep:263:105522.

doi: 10.1016/j.tvjl.2020.105522. Epub 2020 Aug 25.

¹ Department of Clinical Sciences, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada. Electronic address: berenice.conversy@umontreal.ca.
² Department of Clinical Sciences, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada.
³ Department of Pathology and Microbiology, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada.
⁴ Department of Veterinary Biomedicine, Université de Montréal, Saint-Hyacinthe, J2S 2M2, QC, Canada.

No abstract available

Conflict of interest statement

Declaration of Competing Interest The authors report no declarations of interest.

Anticoagulant activity of oral rivaroxaban in healthy dogs.
Conversy B, Blais MC, Dunn M, Gara-Boivin C, Del Castillo JRE. Conversy B, et al. Vet J. 2017 May;223:5-11. doi: 10.1016/j.tvjl.2017.03.006. Epub 2017 Mar 31. Vet J. 2017. PMID: 28671072 Clinical Trial.